2025 third_quarter Filing
Q3Income
$40K
Filed
October 20, 2025
Lobbying Activities
Health IssuesView all
Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to the regulation of hemp-derived cannabinoids, including H.R.4121/S.2256 - FY26 Agriculture, FDA and Related Agencies Appropriations. H.R.946 - ORPHAN Cures Act.
Contacted:Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA)
Lobbyists (2)
HAZEN CLAY MARSHALL
Policy Director-Senate Majority Leader Mitch McConnell; Staff Director/Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP
Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint